C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) is the main treatment option for patients with metastatic renal cell carcinoma (mRCC); however, significant heterogeneity in response is commonly observed. This study aimed to evaluate the ability of C-reactive protein (CRP) to predict overall survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuhelwa, Ahmad Y., Bellmunt, Joaquim, Kichenadasse, Ganessan, McKinnon, Ross A., Rowland, Andrew, Sorich, Michael J., Hopkins, Ashley M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376479/
https://www.ncbi.nlm.nih.gov/pubmed/35978814
http://dx.doi.org/10.3389/fonc.2022.918993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9376479/
https://www.ncbi.nlm.nih.gov/pubmed/35978814
http://dx.doi.org/10.3389/fonc.2022.918993

Ejemplares similares